ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ERNA Eterna Therapeutics Inc

1.7899
0.0542 (3.12%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 15,069
Bid Price 1.70
Ask Price 1.77
News -
Day High 1.89

Low
0.840101

52 Week Range

High
3.45

Day Low 1.5801
Company Name Stock Ticker Symbol Market Type
Eterna Therapeutics Inc ERNA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0542 3.12% 1.7899 16:08:12
Open Price Low Price High Price Close Price Prev Close
1.73 1.5801 1.89 1.7899 1.7357
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
107 15,069 $ 1.76 $ 26,539 - 0.840101 - 3.45
Last Trade Time Type Quantity Stock Price Currency
19:29:02 8 $ 1.77 USD

Eterna Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
9.68M 5.41M - 68k -21.68M -4.01 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Eterna Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ERNA Message Board. Create One! See More Posts on ERNA Message Board See More Message Board Posts

Historical ERNA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.052.23611.58011.917,264-0.2601-12.69%
1 Month2.472.501.58012.104,665-0.6801-27.53%
3 Months1.782.571.432.008,4780.00990.56%
6 Months1.482.570.8401011.5121,9270.309920.94%
1 Year3.003.450.8401011.9120,459-1.21-40.34%
3 Years4.207.150.8401013.7838,571-2.41-57.38%
5 Years4.207.150.8401013.7838,571-2.41-57.38%

Eterna Therapeutics Description

Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using advanced cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Your Recent History

Delayed Upgrade Clock